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ABSTRACT 
 
In this study the criteria of the International Olympic Committee versus the 
Spanish Society of Pneumology and Thoracic Surgery are exposed. 
A study was conducted in eighty high performance athletes of several sports. 
They underwent a medical history, resting spirometry and a methacholine 
challenge test. Sensitivity and specificity of methacholine test were analyzed by 
using Receiver Operating Curves (ROC curves). International anti-doping 
Committee requires that the decline is with a PC20 < 4mg/ml, while for clinical 
practice this fall must present a PC20 < 8mg/ml. 
Rev.int.med.cienc.act.fís.deporte - vol. 14 - número 55 - ISSN: 1577-0354 
496 
 
Twenty five percent of the sportsmen studied had a PC20 > of 8mg/ml; 61% had 
a PC20 < 4mg/ml; and 14% had between 4 and 8mg/ml PC20. The best cut-off 
point was found for a PC20 of 7.6 mg/ml with a specificity of 98.3 and a 
sensitivity of 100%. 
 
The same criteria should be determined to diagnose both sportsmen and 
nonathletes. 
 
KEY WORDS. Bronchial hyperresponsiveness. Trained Athletes. Methacholine 
Test. PC20. 
 
RESUMEN 
 
En este trabajo se exponen los criterios de positividad del Comité 
Olímpico Internacional versus a la Sociedad Española de Neumología y Cirugía 
Torácica.  
 
Participaron en este estudio ochenta deportistas de alto rendimiento, 
realizando una historia clínica, una espirometría de reposo y un test de 
metacolina. Se analiza la sensibilidad y especificidad del test de metacolina 
mediante curvas ROC. El comité Internacional antidopaje (WADA) requiere que 
la disminución sea con un PC20 < a 4mg/ml, mientras que para la práctica 
clínica este descenso debe presentar un PC20 < 8mg/ml.  
 
Los resultados fueron: 25% tuvieron un PC20 > de 8mg/ml; el 61% 
obtuvieron un PC20 < 4mg/ml y un 14% presentaron un PC20 entre 4 y 8mg/ml, 
correspondiendo el mejor punto de corte a PC20 de 7,6mg/ml con especificidad 
de 98,3 y sensibilidad de 100%.  
 
Se tendría que determinar los mismos criterios para el diagnóstico de los 
deportistas y los que no lo son. 
 
 
INTRODUCTION 
 
The increased use of β2 agonists among sportsmen in all sporting disciplines 
promoted the fact that the International Olympic Committee Medical 
Commission established restrictions in the use of this medication. From the 
2002 Winter Olympic Games onwards, especial documentation was requested 
in order to get a Therapeutic Use Exemption (TUE) approval for its use1,2. 
Sportsmen had to present their case history together with the verification of 
obtaining a positive result in one of the following bronchial provocation tests: 
stress test, methacholine test, isocapnic voluntary hyperventilation test and/or 
bronchodilation test, and from 2009 the results obtained in the mannitol test 
were also valid. Sportsmen’s appropriate treatment is really important, not only 
to control and prevent symptoms, but also to reduce the effects on their sports 
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performance3. 30% of the TUE obtained in Athens 2004 Olympic Games were 
carried out through a methacholine test4,5.  
 
In order to carry out an accurate diagnosis of bronchial hyperresponsiveness 
through the methacholine test, it is necessary to set a cut-off point, since 
prevalence of this pathology changes among sportsmen. Therefore, the World 
Anti-Doping Agency (WADA) only accepts the diagnosis of bronchial 
hyperresponsiveness (BH) if obtained by a methacholine test when the forced 
expiratory volume in one second (FEV1) decreases more than 20% and the 
PC20 is ≤ 4 mg/ml. If the sportsman is taking steroids, the PC20 allowed during 
three months is ≤ 6.6mg/ml. According to the Spanish Society for Pneumology 
and Thoracic Surgery (SEPAR), BH is considered positive if there is 20% 
decrease of FEV, and Methacholine concentration (PC20) lower than 8 mg/ml. 
Sportsmen with a PC20 between 4 and 8 mg/ml in our clinical sphere would 
present a diagnosis of bronchial hyperresponsiveness with the appropriate 
treatment, although if they are under the guidelines of international bodies they 
will be penalized. 
 
From 1st January 2010 sportsmen were offered the possibility of BH treatment 
with salbutamol or salmeterol with no restrictions at all. Meanwhile, in order to 
use terbutaline and formoterol, TUE was required6-9. It is well known that the list 
of forbidden substances and requirements to obtain the TUE are revised by 
WADA every year and are constantly changing. 
 
The aim of this project was to study the following matters: a) were this project’s 
sportsmen accurately treated or were they treated above or below treatment 
threshold?; b) determining bronchial hyperresponsiveness’s prevalence 
according to WADA and SEPAR’s criteria; c) if WADA requires again TUEs to 
treat with any bronchodilator, which cut-offs would be the most appropriate to 
avoid inequality between sportsmen and nonathletes?: d) is this medication 
beneficial for all sportsmen or only for those who suffer from bronchial 
hyperresponsiveness? 
 
PATIENTS AND METHODS 
 
This prospective study was carried out in the Andalusian Centre for Sports 
Medicine in Malaga (CAMD), with the approval of the Ethics Committee of the 
Andalusian Centre for Sports Medicine, from the Regional Ministry of Tourism, 
Commerce and Sport of the Junta de Andalucía, under the Declaration of 
Helsiki’s guidelines. Before the start of this study an informed consent was 
signed by each individual or by parents or legal guardians of minors. 
There were 80 federated sportsmen from different sports participating in this 
study (Figure 1): 5% were triathlon athletes, 7.6% rowers, 5% canoeists, 
48.80% were swimmers, 2.5% practiced weight-lifting and wrestling, 7.5% 
practiced team sports, 8.6% were cyclists and 15% athletes; all came from high-
performance sport programmes at the moment of the study. 
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Figure 1.- Percentage of sportsmen from different sports 
 
Sportsmen were recruited from sport clubs in Malaga by sending them an 
invitation letter to participate in the study and from Malaga’s CAMP were 
sportsmen’s medical examination was performed. The inclusion criteria for this 
study were the following: to be between thirteen and thirty years old, to be 
federated, to recruit men and women, to belong to a high performance 
programme, to compete at regional, national or international level and to 
present shortness of breath during or after exercise. The study was carried out 
during a year. 
 
Sportsmen included were between thirteen and thirty years old, and the 
average age was 18 years old. A case history was performed with each 
participant including their identity papers, gender, age, sport performed, level of 
competition, family history and personal history with especial attention to 
asthma and allergies diagnosed, respiratory symptoms and treatments followed 
for these pathologies. None of them were smokers. Sportsmen should stop their 
BH treatment from twenty-four to seventy-two hours before carrying out the 
methacholine test; time depends on the average life of the medicine used. 
 
A physical examination is performed; it includes the following tests: 
 
1) Basic Anthropometry. The measurement of these variables follows the 
protocol recommended by the Spanish Group of Cineanthropometry10. In order 
to perform the anthropometric analysis scales and a Seca measuring rod (Seca 
Ltd, Germany) with an accuracy of 1mm. 
 
2) A resting electrocardiogram test was carried out, participants’ blood pressure 
was taken, and inspection, percussion and auscultation of cardiopulmonary 
apparatus were performed. 
 
3) Then, a forced basal spirometry was performed. Default values were defined 
according to the SEPAR’s6 recommendations as the best values found after 
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performing three spirometries. The FEV1 value obtained in it is the one we take 
as reference when carrying out the methacholine test in order to obtain the test 
result (positive or negative). 
 
4) Methacholine Test. A Datospir 120 spirometer and a Hico-Ultrasonat 806 
nebulizer were used. Before the test the room’s temperature, humidity and 
pressure were checked with a Termofix thermometer and hygrometer and with 
a Cyco barometer. Sportsmen has rested at least twelve hours without training 
before the test. Those participant taking BH treatment had to stop it before the 
test (24, 48 or 72 hours before the test depending on the average life of the 
medicine used). Methacholine test was performed according to the protocol of 
continuous aerosol generator with intermittent inhalations recommended by 
SEPAR. 
 
Methacholine dilutions were prepared from drug dispensed in powder. With this 
aim, four dilutions were prepared. In the first one or Medicine Bottle A a 
hundred milligrams of methacholine were dissolved in two hundreds milliliters of 
saline solution; the result was a concentration of 5mg/ml. In Medicine Bottle B 
we put ten milliliters from Bottle A with ten milliliters of saline solution, with the 
result of a concentration of 2.5mg/ml. In Medicine Bottle C, there were two 
milliliters from Bottle B together with eighteen milliliters of saline solution, 
resulting on a concentration of 0.25mg/ml. In Medicine Bottle D, there were teo 
milliliters from Bottle C and eighteen milliliters of saline solution, obtaining a 
concentration of 0.025mg/ml. Sportsmen are urged to perform five inhalations. 
The first one is performed with saline (the results of this first inhalation act as 
the reference point). These inhalations are followed by each concentration of 
methacholine, starting with the lowest. Three minutes after finishing inhalations 
with the lowest concentration the decrease of FEV1 with regards to the 
reference point is checked; if the result is positive, i.e. if the decrease of FEV1 is 
higher or equal to 20% the test stops, if it is negative, participants continue with 
concentration in Bottle C following the same method until obtaining a positive 
result or a negative result with the highest concentration, the concentration 
corresponding to Bottle A. 
 
Statistical analysis 
 
For the analysis of the data obtained in this study we used both SPSS version 
11.0 (SPSS Inc, IL, USA) and MedCal version 7.3 (Mariakerke, Belgium). First, 
descriptive data on mean, standard deviation, maximum, minimum, and ranges 
for all variables studied were obtained. After that we determined whether the 
variables studied were within normal through the Kolmogorov-Smirnov test. 
Then, the ROC curves were performed to determine sensitivity (proportion of ill 
sportsmen with a positive test result), specificity (percentage of sportsmen 
without disease who obtain a negative test result), positive predictive value, 
negative predictive value and cutoff of PC20 values obtained by methacholine 
test. The Area Under the Curve (AUC) is defined as follows: 0.90 – 1.00 = 
excellent; 0.80 – 0.90 = good; 0.70 – 0.80 = medium; 0.60 – 0.70 = poor; < 0.60 
= very poor. 
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RESULTS 
 
The characteristics of the sportsmen included in the study are shown in Table 1. 
 
Table 1: Sportsmen’s characteristics: average and standard deviation. 
 Women (n=32) Men (n=48) 
Size (cm) 163,53 ± 6,20 175,65 ±   7,03 
Weight (Kg)   58,28 ± 8,71   71,05 ± 10,14 
IMC (Kg/m2)   21,72 ± 2,34   23,02 ±   2,90 
Asthmatic/alergic 0% 21,3% 
 
21.3% of them were diagnosed with asthma, alergy and/or bronchial 
hyperresponsiveness by their family doctor (through symptomatology) or by 
their allergist through skin tests. The rest, 63 (78.75%) were healthy.  
20% of the studied sportsmen (all previously diagnosed by their doctor) had 
medication prescribed for this pathology. 15% were taking β2 adrenergic 
agonists and 5% were using inhaled corticosteroids and β2 adrenergic agonists. 
From this 5%, 3% were being vaccinated and they had been diagnosed by an 
allergist. 1.3% had no medication prescribed although they had been previously 
diagnosed with asthma. It is shown in Figure 2. 
 
 
Figure 2.- Sportsmen’s treatment 
 
All sportsmen who had been diagnosed with asthma or alergy obtained a 
positive result in the methacholine test with a PC20 < 4mg/ml. 39.7% of the 
sportsmen not previously diagnosed were diagnosed with bronchial 
hyperresponsiveness through a bronchial challenge testing, obtaining also a 
PC20 < 4mg/ml. All in all, 61% of the studied sportsmen were positively 
diagnosed with bronchial hiperresponsiveness with PC20 < 4mg/ml. 14% of the 
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sportsmen not previously diagnosed obtained a PC20 between 4 and 8 mg/ml; 
pulmonologists would diagnose them with bronchial hyperresponsiveness while 
WADA would not. Finally, 25% of those not previously diagnosed  presented a 
PC20 higher than 8 mg/ml. (Figure 3) 
 
 
Figure 3.- Percentage of sportsmen according to their PC20 
 
From the eighty methacholine tests carried out, seventy (75%) obtained a 
positive result and 20 (25%) obtained an objective negative diagnostic test for a 
methachonile concentration lower than 8 mg/ml. Lung function parameters after 
having performed the test with sportsmen both with and without bronchial 
hyperresponsiveness is shown in Table 2. 
 
Table 2: PC20: concentration of methacholine required to decrease FEV1 by 20% . FVC: forced 
vital capacity. FEV1: forced expiatory volume in 1 second. FEF25-75: forced expiratory flow 
between 25-75%. MEF50: Maximal Expiratory Flow at 50%. 
 Positive Negative p 
FVC (L) 3.50 4.40 n.s. 
FEV1 (L)   2.70 3.60 p<0.05 
FEF25-75 (L/s) 2.50 7.90 p<0.05 
MEF50 (L/s)  270 3.80 p<0.05 
PC20 (mg/ml) 6.08 14.05 P<0.05 
     
 
The study of sensitivity and specificity of these data using ROC curves are 
shown in Table 3. The best cutoff defined as the best sensitivity and the best 
specificity was for a concentration of methacholine between 4 and 8 mg/ml with 
a sensitivity of 100% and a specificity of 98.3%, with an area under the curve of 
0.99, which means it is excellent. 
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Table 3: Sensitivity and specificity according to the concentration of methacholine. 
 < 4 mg/ml 4 - 8 mg/ml > 8 mg/ml 
Sensitivity (%)   38.20 100.00  55.60 
Specificity (%) 100.00    89.30 100.00 
Cutoff     3.90     7.61   14.78 
AUC      0.74     0.99     0.82 
 
Standard error, positive predictive value, negative predictive value and negative 
likelihood ratio are presented in Table 4. 
 
Table 4: Standard error (SE), Positive predictive value (PPV) and Negative predictive value 
(NPV), and Negative likelihood ratio (-LR) of the concentration of methacholine. 
 SE PPV NPV -LR 
< 4 mg/ml 0.000   38.2 (29.6-  50.7) 100.0 (92.1-100.0) 0.00 
4 - 8 mg/ml 0.001 100.0 (93.7-100.0) 94.7 (74.0-  99.9) 0.01 
> 8 mg/ml 0.000 100.0 (69.2-100.0) 86.4 (75.7-  93.6) 0.47 
 
DISCUSION 
 
Under-treatment of asthma in sedentary patients is a very common 
phenomenon11,12, but it is not known if sportsmen  suffering bronchial 
hyperresponsiveness are undertreated. The literature13-15 consulted reported 
that sportsmen with bronchial hyperresponsiveness are not properly treated. 
O’Byrne16 advises to treat bronchial hyperresponsiveness following international 
protocols in order to avoid under- or over-treatment. 
 
Some studies have shown extensive use of this medication among elite 
athletes. Helenius13 studied several Olympic Games and found that there are 
between 4 and 15% of sportsmen treated of bronchial hyperresponsiveness. 
Weiler14 gave a questionnaire to six hundred and ninety nine sportsmen from 
the Olympic Games in 1996, obtaining as a result that 16.7% of them were 
taking medication for asthma. Therefore, he concluded that this pathology is 
more common among sportsmen than in the general population. 
 
Others indicate they are being undertreated, especially if the point of reference 
is the test for objective diagnosis. Anderson5 compared the percentage of 
sportsmen with prescribed treatment for bronchial hyperresponsiveness in the 
2000 Olympic Games to those who followed a treatment in the 2004 Olympic 
Games and he found that the number of sportsmen had decreased, since they 
had to present an objective diagnostic test of bronchial hyperresponsiveness in 
order to obtain a Therapeutic Use Exemption approval. 
 
Lund15 analyzed four hundred and eighteen Danish elite sportsmen from 
endurance sports through a questionnaire. He showed that these sportsmen 
were generally undertreated. 
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Thomas17 carried out a study with German sportsmen who participated in the 
2008 Olympic Games. He found that 17% of them were diagnosed with 
bronchial hyperresponsiveness. However, only 10% of them were following a 
treatment, so they were then generally undertreated. 
 
The results obtained in this study are in accordance with the above mentioned: 
75% of the sportsmen analyzed were diagnosed through the methacholine test, 
although only 21.3% of them were following a prescribed treatment; therefore, 
the percentage of under-treatment is 53.7%. 
 
It is known that β2 agonists are effective bronchodilator drugs.  However, 
sportsmen should use them occasionally, i.e. only when they have the 
symptoms, and it is recommended to use preventive therapy the rest of the 
time. The IOC has observed that there is an extended and bad use of these 
drugs which cause tolerance to this medication. Recommendations for bronchial 
hyperresponsiveness treatment among sportsmen are to maintain them 
controlled in order to ensure the effectiveness of the treatment and to treat them 
with the lowest effective dosage in order to control their symptomatology18. 
Clark19 published an article in which, after reviewing both the bibliography and 
the last decade experience’s point of view, he recommends patterns of 
education and behavior in order to take better control of bronchial 
hyperresponsiveness and to improve the use of pharmacological treatment. The 
recommendations are the following: to recognize the signs and symptoms of 
disease, to know their FEV1 before starting a training or competition and to limit 
exposure to agents that cause the disease. 
 
Several studies20,21 show that bronchial hyperresponsiveness in sportsmen is 
increasing due to the combination of the rise of ventilation owing to the intensive 
training and environmental factors22. The number of sportsmen with bronchial 
hyperresponsiveness is likely to increase and do the number of sportsmen 
under treatment. The use of β2 adrenergics will be controlled by the IOC 
through doping controls where a maximum of 1600 micrograms of salbutamol 
every 24 hours will be allowed, and every bad use of these drugs will probably 
be detected. That has echoes of what happened with pseudoephedrine in 2004, 
when it was removed from the list of prohibited substances, although it was 
included again in 2010. We now wonder whether with β2 adrenergics will 
happen the same and we will have to use an objective diagnostic test in order to 
use them. In that case, which criteria should be standardized? 
 
1. The prevalence of bronchial hyperresponsiveness according to WADA and 
SEPAR criteria 
 
TUEs were required to justify treatments using β2 agonists and inhaled 
corticosteroids amongst elite sportsmen5, 23-26 until January 2010. Nowadays, in 
order to use salbutamol and salmeterol this approval is not necessary8. In order 
to use any other medication is it compulsory to present a TUE and to obtain it a 
positive objective diagnostic test is required. One of those diagnostic tests is the 
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one we use in this study; the methacholine test. However, we have realized that 
there is a problem regarding the criteria established by this method to obtain a 
positive result. FEV1 must decrease more than 20% of the reference value with 
a concentration lower than 4mg/ml in order to be approved by the IOC. 
However, according to SEPAR, this concentration must be lower than 8mg/ml. 
Only the sportsmen whose concentration is lower than 4mg7ml obtain a TUE, 
which causes a grievance situation amongst sportsmen whose concentration is 
between 4 and 8mg/ml, since they would be considered to suffer from bronchial 
hyperresponsiveness if they were not athletes. Following the IOC’s criteria, we 
found that 61% and 14% of them presented a PC20 between 4 and 8mg/ml. 
Therefore, according to SEPAR the prevalence of bronchial 
hyperresponsiveness is 75% of the studied sportsmen. In the study carried out 
by Naranjo27 to sportsmen who had been medically examined in the Andalusian 
Centre of Sports in Seville (CAMD Sevilla) there was a third part of these 
sportsmen who could not obtain a TUE because they had a PC20 between 4 
and 8 mg/ml. The American Thoracic Society (ATS) in its procotol28 if the year 
2000 claims that the best concentration of methacholine in order to diagnose 
bronchial hyperresponsiveness is of 8mg/ml. 
 
2. Best cut-off points according to PC20 in order to obtain a TUE 
 
In this study cut-off points are analyzed through ROC curves obtained in the 
PC20 of the FEV1 amongst high performance sportsmen. The best one is a 
concentration of 7.6mg/ml with sensitivity of 100% and specificity of 93.3%. This 
is in accordance with ATS’ protocols. 
 
Bowen29 studied a group of Australian children and the best cut-off point was in 
3.9mg/ml with sensitivity of 86.3% and specificity of 36.4%, but this result was 
obtained with a 15% decline in FEV1. 60% of the children presented a PC20 
lower than 7.8mg/ml. 
 
Godfrey30 studied asthmatic children and young adults through a methacholine 
test and a stress test in order to determine the best cut-off points though ROC 
curves. The best cut-off point was for a PC20 of 3.3mg/ml with sensitivity of 92% 
and specificity of 89%. 
 
Liem31 carried out a methacholine test and a skin test to six hundred and forty 
children who were born in 1995. The best cut-off point was found in 
concentrations lower than 4mg/ml, with sensitivity of 71% and specificity of 
69%. 
 
3. Are there benefits in sports performance with the use of bronchodilators for 
all sportsmen with and without bronchial hyperresponsiveness? 
 
We need to consider whether the use of β2 agonists administered both by 
inhalation and by therapeutic doses have a clear advantage in competitions. 
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Carlsen32 performed a study with sportsmen from endurance sports in which he 
administered formoterol or placebo an hour before carrying out a maximal 
exercise stress test which measured ventilation parameters and performed 
spirometries before and after their exercise and he did not find any change in 
lung mechanics parameters or in the duration of the test. This author suggests 
performing an objective bronchoprovocation test in order to diagnose bronchial 
hyperresponsiveness before recommending a treatment for this pathology. In 
his opinion, there is a great benefit for diagnosed sportsmen, while it is not good 
for healthy sportsmen. 
 
Van Baak33 studied whether a dose of salbutamol before doing sport has an 
effect on endurance during a stress test. The study was carried out with two 
tests: one after inhaling placebo and another one after inhaling salbutamol. The 
results showed that endurance exercise was higher after inhaling placebo.  
 
CONCLUSIONS 
 
The conclusions of this study are the following: 
 
1. In order to perform an accurate treatment positive objective diagnostic tests 
are required. 
 
2. There should be an agreement between the IOC and Pneomological 
Societies to determine the most accurate criteria to diagnose bronchial 
hyperresponsiveness so that it does not continue being a restriction opposite to 
regulations for sportsmen. 
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